Abstract
BackgroundThe combination treatment of golimumab (GOL), a tumor necrosis factor-alpha (TNFα) antagonist, and guselkumab (GUS), an interleukin (IL)-23 inhibitor was shown to induce higher rates of clinical remission, endoscopic improvement,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have